Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05793034

Predictive Factors for Survival in Aggressive Meningiomas

The investigators plan to collect clinical and molecular data, including ICH, PCR, NGS and methylome, from patients operated on for grade 2 or grade 3 meningioma. The purpose of the study is to identify reliable and easy-to-assess predictive factors for recurrence and survival after surgery.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Meningioma Anaplastic Meningioma Central Nervous System Neoplasms Meningeal Neoplasms Meningioma Atypical Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Nerve Tissue Neoplasms, Vascular Tissue Nervous System Diseases Nervous System Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Fondazione Policlinico Universitario A. Gemelli IRCCS

Rome, 00168, Italy

Location status: Recruiting

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient operated for atypical (grade 2) meningioma; or
  • Patient operated for anaplastic (grade 3) meningioma;
  • Timeframe for surgery, 1999-2019

Exclusion criteria

  • Patient lost at follow-up

Treatment and study plan

Biological biomarker assessment

Diagnostic Test

IHC, PCR, NGS, methylome

Primary outcomes

  1. Recurrence-free survival (RFS)

    Time frame: 5 years on average

    Correlation from biomolecular data and RFS

Secondary outcomes

  1. Overall survival (OS)

    Time frame: 5 years on average

    Correlation from biomolecular data and OS

Interested in participating?

Recruiting

Interested in participating?

Request Info

Sponsors and collaborators

Lead sponsor

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Other

Registry information

Official study title

Analysis of Predictive Factors for Overall and Progression-free Survival After Neurosurgery for Atypical or Anaplastic Meningioma

Acronym: 23Men

Important dates

Study start
2021
Primary completion
2026
Study completion
2027
First posted
Mar 31, 2023
Registry last updated
Mar 13, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.